This project is part of the EDCTP3 programme supported by the European Union

SAFIRE impact

Who will benefit

Who will benefit from the results of the SAFIRE project?

  1. Pregnant women in their first trimester with uncomplicated malaria and their babies, as well as women of childbearing potential with unknown pregnancy status.
  2. Healthcare professionals and drug prescribers/dispensers providing care and treatment for pregnant women and those of childbearing age who could be pregnant.
  3. Policymakers, including the WHO Global Malaria Programme and National Malaria Control Programmes in endemic countries.
  4. The scientific community involved in the fields of malaria, drug safety in pregnancy and trial methodology.

Leveraging SAFIRE project results

How will the successful dissemination and exploitation of SAFIRE project results impact the target group?

  1. The SAFIRE project will support the widespread adoption of research results into national and international malaria treatment guidelines for pregnant women.
  2. The uptake of research results into clinical practice will give pregnant women in sub-Saharan Africa the best medicines to prevent adverse pregnancy outcomes and deaths, in a timely manner.
  3. Clinicians and researchers in sub-Saharan Africa will have the capacity to design and implement adaptive platform trials, and work alongside ethics committees, regulators and policymakers.

Expected outcomes

What are the expected wider scientific, economic and societal outcomes of the project?

  1. Support the achievement of the UN Sustainable Development Goal 3, ‘Ensure healthy lives and promote well-being for all at all ages’ in malaria-endemic countries through the effective treatment of the disease in the first trimester of pregnancy.
  2. Advance the 2030 Malaria Global Technical Strategy through the development of evidence-informed health policies and guidelines within public health systems in sub-Saharan Africa and at the international level.
  3. Contribute to reducing preventable morbidity and mortality associated with malaria in pregnancy, benefiting not only women in the first trimester, but also their unborn babies, women with unknown pregnancy status and the wider community.
  4. Enhance operational capability to rapidly assess new antimalarial treatments in pregnancy.
  5. Support the growth of sustainable networks of clinical sites that can undertake research in early pregnancy in sub-Saharan Africa.
  6. Mitigate socioeconomic setbacks caused by malaria infection in early pregnancy by ensuring widespread access to effective treatment.
News

Africa-Europe research partnership delivers first clinical trial for malaria in early pregnancy

The SAFIRE project, funded by Global Health EDCTP3, is generating first-of-its-kind clinical evidence to improve malaria treatment in early pregnancy. In 2024, the estimated number of malaria cases climbed to 282 million, up from 273 million the previous year, with

Read more
Development of Context-Appropriate Recruitment and Retention Approaches for Pregnant Women in the SAFIRE Clinical Trial Assessing Safety and Efficacy of Artemisinin-Combination Therapies: A Formative Research Protocol
Publication

Development of Context-Appropriate Recruitment and Retention Approaches for Pregnant Women in the SAFIRE Clinical Trial Assessing Safety and Efficacy of Artemisinin-Combination Therapies: A Formative Research Protocol

Authors: Jenna Hoyt, Adélaïde Compaoré, Samba Diarra, Freddy Bikioli Bolombo, Susan Nayiga, Serge Henri Zango, Moussa Djimde, Stephanie Dellicour, Japhet Kabalu Tshiongo, Hypolite Muhindo-Mavoko, Abel Kakuru, Simon Kariuki, Hellen Barsosio, Kassoum Kayentao, Innocent Valea, Jenny Hill, and Maud Majeres Lugand

Read more
News

International Day of Women and Girls in Science

SAFIRE is challenging the status quo in clinical research, where women in the first trimester of pregnancy have traditionally been excluded, leaving critical evidence and treatment gaps for malaria in pregnancy. To help make a trial like SAFIRE possible, researchers

Read more
Blood sample collection during screening of the first participant enrolled in the SAFIRE study in Mali. Credit: Parasites & Microbes Research & Training Center (Mali).
News

First patient enrolled in historic Phase 3 clinical trial to treat malaria in first-trimester pregnancy

Major milestone in Africa’s first-ever study assessing malaria treatments in early pregnancy Through the SAFIRE consortium, experts from Africa and Europe are closing a critical treatment gap for women in early pregnancy. Each year, over 12 million pregnant women are

Read more
Event

SAFIRE scientific symposium: 12th EDCTP Forum

Speakers and presentations Shaping the future: advancing equitable and ethical research to meet women’s therapeutic needs Location: Kigali Convention Center, Room MH3Date & time: Tuesday, 17 June from 16:30 to 18:00 Dr Stephanie Dellicour, Principal Research Associate, Liverpool School of

Read more
News

Africa-Europe partnership to launch historic Phase 3 clinical trial in early pregnancy

In a world first, a global consortium plans to undertake a Phase 3 clinical trial assessing antimalarial medicines in women in their first trimester of pregnancy The trial will evaluate the efficacy, safety, tolerability and cost-effectiveness of antimalarial drugs to

Read more
View all
Linkedin-in

Subscribe to the SAFIRE newsletter

* indicates required

Please select all the ways you would like to hear from :

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.